Veritas Health Economics Consulting, Carlsbad, CA, USA.
UTHealth McGovern Medical School, Houston, TX, USA.
Future Microbiol. 2018 May;13:617-629. doi: 10.2217/fmb-2017-0238. Epub 2018 Jan 10.
We assessed the possible economic impact of a rapid test in pediatric patients with suspected community-acquired meningitis/encephalitis.
MATERIALS & METHODS: Modeling simulated diagnosis, clinical decisions, resource use/costs of standard of care (SOC) and two cerebrospinal fluid testing strategies using FilmArray (FA), a US FDA-cleared system that provides results in approximately 1 h.
Pathogens detected by FA caused approximately 75% of cases, 97% of which would be accurately diagnosed with FA. Mean cost/case ranged from $17,599 to $22,025. Syndromic testing is less expensive than SOC. Testing all suspected cases yielded greater savings ($3481/case) than testing only those with abnormal cerebrospinal fluid ($2157/case).
Greater economic benefits are achievable with syndromic testing of all cases, rather than SOC or targeted syndromic testing.
我们评估了疑似社区获得性脑膜炎/脑炎的儿科患者中快速检测可能产生的经济影响。
模型模拟了诊断、临床决策、标准护理（SOC）的资源使用/成本以及两种使用 FilmArray（FA）的脑脊液检测策略，FA 是一种获得美国 FDA 批准的系统，可在大约 1 小时内提供结果。
FA 检测到的病原体约占 75%，其中 97%的病原体可以通过 FA 准确诊断。平均每个病例的费用为 17599 美元至 22025 美元。综合检测比 SOC 更便宜。与仅检测异常脑脊液的方法（每个病例节省 2157 美元）相比，对所有疑似病例进行综合检测可节省更多费用（每个病例节省 3481 美元）。
与 SOC 或有针对性的综合检测相比，对所有病例进行综合检测可以带来更大的经济效益。
